source; lin
  • Sirona Biochem (SBM) terminates supply agreement with Rodan + Fields
  • Allergan Aesthetics will now be the sole licensee of the technology as per the agreement signed in June 2022
  • There may be potential for more news to be released regarding this termination at a later date
  • Sirona Biochem is a cosmetic ingredient and drug discovery company with proprietary platform technology
  • The company strives to patent new compounds for maximum revenue potential
  • Sirona Biochem (SBM) is up 23.81 per cent, trading at C$0.13 at 1:57 pm EST

Sirona Biochem (SBM) has terminated the Rodan + Fields (R+F) agreement for the supply and use of TFC-1067 in commercial formulations.

Allergan Aesthetics, an AbbVie company (NYSE: ABBV), will now be the sole licensee of the technology as per the agreement signed in June 2022.

There may be more news regarding the termination at a later date.

Sirona Biochem is a cosmetic ingredient and drug discovery company with proprietary platform technology.

Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety.

The company strives to patent new compounds for maximum revenue potential.

Sirona Biochem (SBM) is up 23.81 per cent, trading at C$0.13 at 1:57 pm EST.

More From The Market Online

KWESST to provide situational awareness for the Canadian Red Cross

KWESST Micro Systems (TSXV:KWE) wins a contract to provide a situational awareness app to support the Canadian Red Cross.

Air Canada stock rises as service from Ottawa grows

Air Canada (TSX:AC) boosts its schedule serving Ottawa by almost 60 per cent with more flights across the nation.

Odd Burger to add 40 locations in Florida

Odd Burger (TSXV:ODD) will develop 40 new locations in Florida over the next eight years, with its sights set on further U.S. expansion.